The challenge
An early-stage AI platform for pharma compliance was up against established vendors. Buyers worried about data security and about AI replacing expert judgement, and the founders' own LinkedIn posts were not reaching decision makers.
What we did
- Researched 5,500 R&D, compliance, QA and C-suite contacts by hand and segmented them by role and company size.
- Wrote messages that answered the security and AI objections before they were raised.
- Ran LinkedIn and email side by side for six months.
- Reached5,500 R&D, compliance, QA and C-suite contacts
- Accepted20% of LinkedIn invitations
- Replied19% of connections wrote back
- Qualified42 sales qualified leads
What worked
When the message already answers the security question, the reply is about the product.
What slowed results, and what we changed
What slowed it
Buyers worried about data security, and about AI replacing expert judgement.
What we changed
The first message answered both questions before they were raised.
Client names are kept private. Each campaign was led by our founder, and every figure comes from the campaign's own report.
